Geodon, Abilify Have Low Diabetes Risk, ADA Says; Lilly Disagrees

An American Diabetes Association "consensus" statement on antipsychotics and the risk of diabetes may help Pfizer and Bristol-Myers Squibb make the case to FDA to exempt Geodon and Abilify from class labeling